FDA approves first generic Advair Diskus4 Feb 2019
Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.
Mylan has announced the FDA approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of Advair Diskus.
Wixela Inhub will launch in the second half of February incorporating the latest safety information required by FDA last month, which prompted an amendment to the label for certain inhaled corticosteroids, including Advair Diskus and any generic versions. Wixela Inhub will be available in the 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths for asthma patients and the 250 mcg/50 mcg strength for COPD patients.
Mylan CEO Heather Bresch commented: "Mylan remains steadfast in its efforts to expand patient access to medicines, and the FDA approval of Wixela Inhub reinforces our commitment to provide patients greater choice and lower-cost alternatives. This milestone represents the culmination of an extensive R&D program and Mylan's more than $700 million of investment. We're proud of our Wixela Inhub team, who worked tirelessly and in close collaboration with the FDA to bring this important medicine to market and add it to our growing global portfolio of more than 700 respiratory products. As one of the leading providers of prescription medicines in the US, we continue to execute on our mission and do our part to reduce costs for patients and identify pathways that help increase sustainability for the US healthcare system overall."
Mylan President Rajiv Malik added: "We're pleased to offer the first FDA-approved generic of Advair Diskus, one of the leading treatments for asthma and COPD management today. We've long been confident in the science around this product and are proud of the dedication of our scientific teams to bring Wixela Inhub to market. This complex product required a rigorous R&D program spanning over a decade and close collaboration with FDA to define the regulatory pathway. We also are proud to manufacture Wixela Inhub in our own state-of-the-art plant. This approval reinforces our ongoing commitment to increase access to more affordable treatment options for patients."
"Patients enrolled in clinical trials found Wixela Inhub easy-to-use and highly effective at controlling their asthma in a clinical bioequivalence study. Asthma and respiratory specialists and primary care providers welcome this generic alternative to benefit many patients with asthma and COPD. We have waited for years for generic inhalers to emerge in respiratory medicine," said Edward Kerwin, MD of Crisor, a division of the Clinical Research Institute located in Medford, Ore. and a Clinical Investigator on the Wixela Inhub clinical program.
Advair Diskus had US sales of $4.2 billion for the 12 months ending 30 November 2018, according to IQVIA.
Pinpoint secures new investment to develop "ground-breaking" products
29 Nov 2019
The financial backing will help the company to develop a new generation of microbial air monitors that enables continuous monitoring as demanded by the Annex 1 revision.Read more
New single-use mixing system offers rapid and homogenous mixing
28 Nov 2019
ClearMixx performs liquid/liquid and powder/liquid mixing, with a dispersion plate able to efficiently mix the most challenging buffer, media and biopharmaceutical ingredients.Read more
Worldwide event predicts global pharma trends for 2020
27 Nov 2019
Content sessions identify value-added medicines, preventive drugs, early diagnostics and patient experience as some of the trends for the year ahead.Read more
UK’s life sciences sector continues to attract talent despite Brexit fear
26 Nov 2019
The largest area of growth has been within biotechnology companies, where job openings increased by 35%.Read more
Dr Reddy’s enters Nutrition Segment with diabetes drink
25 Nov 2019
The company's diabetes nutrition drink, Celevida, is formulated to help manage blood glucose levels.Read more
India pharma forecast to grow strongly in 2020
22 Nov 2019
The rise in exports growth potential is believed to be in response to concerted reforms by the CDSCO and industry quality improvements in the last few years.Read more
Heraeus expands its platinum-based HPAPI capacity
21 Nov 2019
Company's multimillion euro investment will enable it to meet growing market demands from clients providing cancer treatments.Read more
Thermo Fisher Scientific opens Customer Solution Center in China
20 Nov 2019
The new center will provide expertise in critical analytical processes and specialized workflows.Read more
Is Recipharm on the cusp of becoming a leading inhalation company?
19 Nov 2019
The CDMO offers to acquire Consort Medical to become a Top Five global CDMO player.Read more
Hovione completes pilot-scale blister manufacturing for its 'green' DPI
19 Nov 2019
The device's blister is designed to provide flexibility to pharmaceutical partners delivering a wide range of inhaled drugs for both acute and chronic respiratory treatments.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation